Articles On Cynata Therapeutics (ASX:CYP)

Cynata Therapeutics flags three trial results in the short term for three different conditions, including diabetic leg ulcers Prescient Therapeutics prepares for a blood cancer trial and potential fast-track approval Pacific Edge chairman...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

Volatility remained the status quo as the ASX200 ended down 0.23%. The local bourse briefly touched into the green after lunch, but the mood was short-lived. The market almost immediately pared gains, sinking back into the red. There...

The ASX dropped, dragged down by Real Estate and Mining stocks Qantas cuts former CEO’s compensation by $9.3m Fears of a US recession are growing, with the Sahm Rule signalling potential trouble   A selloff in Real Estate and Mining stock...

Cynata Therapeutics Ltd (ASX:CYP) has seen its share price rise more than 10% on the release of a study indicating the potential for Cymerus – its ‘off the shelf’ therapeutic stem cell platform technology – to reverse pulmonary fibrosis and...

  To register for Friday's webinar click here. NOVONIX (ASX:NVX) and CBMM has joined forces to develop cost-effective, high-performance cathode materials. NOVONIX's patented process will combine with CBMM's niobium to create high-performanc...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

Imricor completes installation of iCMR capital equipment at Lausanne University Hospital in Switzerland PYC Therapeutics says safety data from patient cohort four successfully reviewed with recommendation trial continues Cynata Therapeutic...

ASX rose  as the RBA held interest rates at 12-year high 4.35pc All 11 sectors on the ASX gained, with significant moves from Pilbara and Fortescue  ASX to launch first bitcoin-linked ETF on Thursday   Aussie stocks bounced back by +0.8%...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

Special Report: A recent lunch put together in Sydney by Jane Morgan Management and Éthica Capital saw a number of the ASX’s most innovative biotech and tech companies present and pitch to an audience of potential investors on the lookout f...

Momentum trading involves taking advantage of, and making profits from, upward trends in a stock. The strategy makes a calculated bet that the stock market’s recent winners will remain winners. The Relative Strength Index (RSI) is a popular...

Investors got the chance to get up close and personal with ASX technology and biotech companies in Sydney recently at the JMM & Ethica Capital Innovation & Investment Insights Lunch. Featuring quick ‘stand up and pitch your story’ s...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

MELBOURNE, Australia, April 8, 2024 /PRNewswire/ — Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the completion of pati...

Biotech company Cynata Therapeutics (ASX:CYP) received regulatory and ethics approval in the European Union (EU) for its Phase 2 clinical trial of CYP-001 in high-risk acute graft versus host disease (aGvHD). CYP-001 is Cynata’s innovati...

Local markets end lower on big bank sell-off Material gains offset by Telco’s and Financials  Small Caps led by rare earths developer Arafura   Local markets have not showered anyone in glory, profit or confidence on Thursday. At 4pm on T...

  Peter Milios: I am Peter Milios from the Finance News Network, and today I am talking with Cynata Therapeutics. Cynata is a clinical stage stem cell and regenerative medicine company. Their ASX code is CYP and they have a market cap of ar...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Cynata Therapeutics’ (ASX:CYP) announces the enrolment and treatment of the first participant (CYP-001) in its Phase 2 clinical trial for high-risk acute graft versus host disease (aGvHD) US FDA has granted clearance for an Investigation...

MELBOURNE, Australia, March 5, 2024 /PRNewswire/ — Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, confirms that the first patient has been enro...

Healius has new CEO Nove Eye reports record US sales in February Cynata says first patient has been enrolled in Phase 2 trial   Healius has a new CEO, shares rip higher Healius (ASX:HLS) jumped 14% this morning after announcing that it wo...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

MELBOURNE, Australia, Feb. 26, 2024 /PRNewswire/ — Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, has completed initial analysis of wound surfa...

Recce Pharma says Phase 1/2 study is achieving primary endpoints Cynata also reports also reports good progress in Phase 1 Cardiex is back on the ASX!   Recce to expand diabetes foot ulcer Phase 1/2 trial An independent Safety Committee h...

  ASX200 trims gains to end circa 0.3pc higher Sectors in the money include Utilities and IT Small cap winners led by Alliance Nickel and Sarytogan Graphite   A fresh batch of fat Q4 profit reports in the US overnight was apparently all t...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

Althea extends contract in Canada Clarity moves forward to cohort 3 Cynata opens Phase 2 recruitment   Althea extends deal in Canada for cannabis drinks Cannabis company Althea Group (ASX:AGH) announced that its wholly owned subsidiary, P...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Medibio jumps after completing Phase 1 clinical trial Cann Group’s latest crop harvest is at a scale twice that of previous harvests 4DMedical wins a $1.1 million from the Fed government   Microcap Medibio (ASX:MEB) jumped 50% this mornin...

The changing of the guard is not just evident at Buckingham Palace: barely a week goes by without an ASX-listed biotech announcing a new person at the helm. In the case of the junior stem-cell therapy developer Cynata (ASX:CYP), incumbent D...

S&P/ASX 200 closes well in the red today: -1.24% after US stocks dipped on the back of Fed hawkishness  Sectors-wise, IT was the only group finishing vaguely in the green, with Materials Discretionary and Financials stocks largely hamm...

Australian clinical-stage cell therapy company Cynata Therapeutics (ASX:CYP) has announced the appointment of Dr Kilian Kelly as its new CEO and managing director.

The ASX200 closed the 2023 financial year marginally higher, ahead of significant Labor Government changes coming into effect from tomorrow. Workers on the minimum wage will be paid nearly six per cent more per hour, while employer’s sup...

Cynata Therapeutics (CYP) appoints Dr Kilian Kelly as its CEO and Managing Director, effective July 1 Dr Kelly has held the role of CYP Chief Operating Officer since May 2019 and has been “instrumental” in advancing the company’s clinica...

Highlights Dr Kilian Kelly has been appointed to the position of Cynata’s Chief Executive Officer and Managing Director Dr Geoff Brooke, Chairman of the ASX-listed entity, commented that Dr Kelly's appointment reflects the "exciting gr...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

The ASX closed out the day flat, thanks to a last-minute selling spree Qantas announces record profit but still won’t give us back the money we gave them during Covid Westar Resources won the Small Caps race, in spite of a 90-minute hobbli...

Highlights Cynata will present two-year patient follow-up data from its Phase 1 clinical trial of CYP-001 in SR-aGvHD at ISCT. ISCT, a major international conference, will be attended by delegates from more than 50 countries. As per...

‘More of the same’ since lunchtime saw the benchmark land at -0.25% for the day Health Care coughed up a 1.09% lift while Financials weighed heavily on -0.71% Magnum Mining wins the Small Caps trophy with +44.1% thanks to Mitsubishi deal...